Roivant Sciences (ROIV) Liabilities from Discontinued Operations (2024)
Roivant Sciences (ROIV) reported Liabilities from Discontinued Operations of 433945000.0 for Q1 2024.
Roivant Sciences (ROIV) Liabilities from Discontinued Operations (2024) Analysis & Trends
Roivant Sciences has reported Liabilities from Discontinued Operations for 1 years, with the latest figure at 433945000.0 in Q1 2024.
- For the quarter ending Q1 2024, Liabilities from Discontinued Operations changed N/A year-over-year to 433945000.0; the trailing twelve-month figure through Mar 2024 stood at 433945000.0 (changed N/A YoY), and the FY2024 full-year result was 433945000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q1 2024 stood at 433945000.0.
- The five-year high for Liabilities from Discontinued Operations was 433945000.0 in Q1 2024, with the low at 433945000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 433.95 Mn |
| Mar 31, 2024 | 433.95 Mn |